Pretty much same thing as US...
The european banks are relatively stronger there than they are in the US (UBS, CS, DB).
BAML and Citi are pretty mediocre.
GS/MS/JPM still are probably the most "prestigious"
One thing to keep in mind though is that in HK, it's probably better to join an industry coverage team versus a product group (i.e. M&A). ECM is the money maker in Asia, a lot of regulatory and cultural problems that hinders M&A deal volume. Financial Sponsors/LevFin = no dealflow. Equity-related deals, by contrast, are very common.
MS and UBS are very strong in HK/China market.
GS has been losing market shares in the past few years, but still has great business presence.
JPM and CS has been catching up in the past two years, especially JPM.
Citi and DB are mediocore in HK/China.
ML has been growing in Asia, but not sure how the new BAML looks like right now.
BarCap, Lehman and Bear used to be the worst BB shops in HK. BarCap has very small market share in HK/China due to their focus on debt products. It is going to take a long time for them to establish their M&A and equity business in full there. Lehman just don't have a good business rhythm outside the US territory... Now the Nomura thing makes it look even worse IMO. Bear is out of discussion now.
UBS and Barcap don't have much presence here anymore
As stated above, its better to start in a industry coverage group or M&A here as opposed to a product group - besides actually getting to learn something it is more "prestigious" and has better exit ops.
True UBS is hiring, but doesn't have much brand value here compared to the other BBs.
Besides the fact that LTs don't really mean anything, the LTs here are mainly dominated by the local banks and some from the top bracket of banks. Anyone can get on the top by joint-bookrunning hundreds of deals
I'm giving you an on ground view here, as recent as last year. Again this is my opinion, but a general consensus across other analysts from other banks here
Pretty inaccurate comments in this thread. UBS and GS are the only two with a real China JV. They do plenty of business and M&A wise (cross-border) GS is crushing it. MS is always going to be up there. UBS is only good because of its private wealth business and is typically non-SOE business
This is not true. MS formed one of the first JVs in China with Huaxin securities in 2011. MS M&A is definitely the place to be if you want to be involved in M&A
MSHX is not on par with UBSS or GSGH. MS formed JV after breaking up with CICC and MSHX does most A shares IPOs. UBSS and GSGH are the only top JVs. HSBC is doing great recently.
Doloribus saepe impedit voluptatem ea iure. Aut vero voluptate alias dicta. Minima ut cumque aliquam dolore omnis eum ea.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
Libero expedita expedita ipsa molestiae nobis. Totam excepturi quis ad dolor. Consequuntur nisi aliquam vitae incidunt. Et harum occaecati explicabo eligendi.
Quisquam unde aliquid nihil. Numquam fuga occaecati cum reprehenderit adipisci eos. Nam odio ut ipsum quia aut.
Similique est sapiente atque corporis commodi beatae maiores voluptatem. Nostrum quos quis nobis. Debitis odio libero earum.
Sorry, you need to login or sign up in order to vote. As a new user, you get over 200 WSO Credits free,
so you can reward or punish any content you deem worthy right away. See you on the other side!
Piper Jaffray.
Why don't you check the league tables? Assuming that by reputation you mean deal volume.
Pretty much same thing as US... The european banks are relatively stronger there than they are in the US (UBS, CS, DB). BAML and Citi are pretty mediocre. GS/MS/JPM still are probably the most "prestigious"
One thing to keep in mind though is that in HK, it's probably better to join an industry coverage team versus a product group (i.e. M&A). ECM is the money maker in Asia, a lot of regulatory and cultural problems that hinders M&A deal volume. Financial Sponsors/LevFin = no dealflow. Equity-related deals, by contrast, are very common.
GS MS UBS CS
whats wrong with PJC? They led couple of deals in HK.
GS, MS and UBS
MS and UBS are very strong in HK/China market. GS has been losing market shares in the past few years, but still has great business presence. JPM and CS has been catching up in the past two years, especially JPM. Citi and DB are mediocore in HK/China. ML has been growing in Asia, but not sure how the new BAML looks like right now. BarCap, Lehman and Bear used to be the worst BB shops in HK. BarCap has very small market share in HK/China due to their focus on debt products. It is going to take a long time for them to establish their M&A and equity business in full there. Lehman just don't have a good business rhythm outside the US territory... Now the Nomura thing makes it look even worse IMO. Bear is out of discussion now.
Thanks for all the replies
UBS is tops
gs, ms, jpm, ubs, cs
ubs used to be rank higher in terms of prestige (altho its still number 1 in ECM, its rep has been damaged since the crisis)
agree that db is pretty mediocre
bump! wondering if the situation is still the same
UBS is still top
UBS going down
bump
has anything changed?
anyone?
GS, MS, BAML and CS are top
Citi and UBS are mediocre
Don't go near DB right now
UBS and Barcap don't have much presence here anymore
As stated above, its better to start in a industry coverage group or M&A here as opposed to a product group - besides actually getting to learn something it is more "prestigious" and has better exit ops.
Noticed you've left JPM out...
JPM is between the top and mediocre bucket now - owing to recent investigations and structural changes. Bonuses at JPM were terrible this year
Also that UBS is hiring there and was top or second on the league tables...
True UBS is hiring, but doesn't have much brand value here compared to the other BBs.
Besides the fact that LTs don't really mean anything, the LTs here are mainly dominated by the local banks and some from the top bracket of banks. Anyone can get on the top by joint-bookrunning hundreds of deals
I'm giving you an on ground view here, as recent as last year. Again this is my opinion, but a general consensus across other analysts from other banks here
GS, MS and UBS
UBS is No1 in mainland China thanks to its JV and set of licenses, ok-ish in Hong Kong
That's a Yes, from what I hear. M&A in general does better here in HK
I see. Thanks for all the replies. You might not be comfortable answering this, but if you don't mind me asking, which BB did you work at?
WhartonOrBust are you going to MS HK? I am debating between a couple of options right now
Pretty inaccurate comments in this thread. UBS and GS are the only two with a real China JV. They do plenty of business and M&A wise (cross-border) GS is crushing it. MS is always going to be up there. UBS is only good because of its private wealth business and is typically non-SOE business
This is not true. MS formed one of the first JVs in China with Huaxin securities in 2011. MS M&A is definitely the place to be if you want to be involved in M&A
MSHX is not on par with UBSS or GSGH. MS formed JV after breaking up with CICC and MSHX does most A shares IPOs. UBSS and GSGH are the only top JVs. HSBC is doing great recently.
HK IBD SA Offers - How to choose and how to rank those BBs there? (Originally Posted: 01/13/2013)
Dear Monkeys,
Solved - cheers. :) :) :) :)
~
Great to see you here Alex haha
~~
bump~
bump
bump bump
bump T_T
I give up... T_T
Doloribus saepe impedit voluptatem ea iure. Aut vero voluptate alias dicta. Minima ut cumque aliquam dolore omnis eum ea.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...
Libero expedita expedita ipsa molestiae nobis. Totam excepturi quis ad dolor. Consequuntur nisi aliquam vitae incidunt. Et harum occaecati explicabo eligendi.
Quisquam unde aliquid nihil. Numquam fuga occaecati cum reprehenderit adipisci eos. Nam odio ut ipsum quia aut.
Similique est sapiente atque corporis commodi beatae maiores voluptatem. Nostrum quos quis nobis. Debitis odio libero earum.
Minus quos magni illum eveniet et perferendis. Molestiae qui et unde aliquam. Itaque eligendi nisi earum totam quo quae.